scholarly journals Salivary inflammatory mediators and metalloproteinase 3 in patients with chronic severe periodontitis before and after periodontal phase I therapy

2013 ◽  
Vol 1 (1) ◽  
pp. 3 ◽  
Author(s):  
Silvia Reina ◽  
Fernando Hoyos ◽  
Nelson Carranza ◽  
Enri Borda
Keyword(s):  
Phase I ◽  
Inflammatory Mediators ◽  
Severe Periodontitis ◽  
Before And After

Antimicrobial Effect of 940 nm Diode Laser based on Photolysis of Hydrogen Peroxide in the Treatment of Periodontal Disease

2018 ◽  
Vol 69 (8) ◽  
pp. 2081-2088 ◽  
Author(s):  
Alin Alexandru Odor ◽  
Edwin Sever Bechir ◽  
Deborah Violant ◽  
Victoria Badea
Keyword(s):  
Hydrogen Peroxide ◽  
Laser Therapy ◽  
Diode Laser ◽  
Antimicrobial Effect ◽  
The Other ◽  
Control Group ◽  
Group 4 ◽  
Periodontal Bacteria ◽  
Severe Periodontitis ◽  
Before And After

Moderate and severe periodontitis represents a challenge in the non-surgical periodontal therapy. Due to the lack of evidence regarding the antimicrobial effectiveness of 940 nm diode laser in periodontal treatment, this study aimed to evaluate the antimicrobial effect of hydrogen peroxide (H2O2) photolysis performed with 940 nm diode laser in the treatment of moderate and severe periodontitis. Twenty-five patients with 100 teeth were selected for this pilot study. The test teeth were randomly assigned to one of the four treatment groups: Group 1: scaling and root planning (SRP) (control group); and the following experimental groups: Group 2: H2O2; Group 3: 940 nm diode laser therapy; Group 4: 940 nm diode laser therapy and H2O2. Clinical examinations, like probing depth (PD), clinical attachment level (CAL) and bleeding on probing (BOP) were performed before and after the treatment. The microbiological evaluation, effectuated before and after the treatment, included nine periodontal bacteria species and investigated by means of real-time PCR assay. The clinical and bacterial differences in the tested groups, was assessed between control group and the other three experimental groups, as well as between the experimental groups. The total bacteria load was reduced for all four studied groups. Group 4 (diode laser + H2O2) showed significant bacterial reduction of the major periodontal bacteria like Pg., Tf., Td., Pi., Pm., Fn (p[0.001) than the other 3 groups (p]0.001). Also the periodontal clinical parameters, like PD, CAL and BOP showed a significant reduction after the photolysis of H2O2 with the 940 nm diode laser (p[0.001). Differences between tested groups showed a significant beneficial results in regard to Group 4.It is suggested that the photoactivation of H2O2 with the 940 nm diode laser can be used successfully in adjunctive to the non-surgical periodontal treatment as a bactericidal tool.

scholarly journals High-intensity Interval Training Improves Inflammatory Mediators in Obese Women: Based on the Study of the UCP2 Ala55Val Gene

2021 ◽  
Vol 9 (A) ◽  
pp. 871-875
Author(s):  
Susiana Candrawati ◽  
Emy Huriyati ◽  
Zaenal Muttaqien Sofro ◽  
Lantip Rujito ◽  
Aulia Nury Faza ◽  
...  
Keyword(s):  
Body Weight ◽  
Inflammatory Mediators ◽  
High Intensity ◽  
Interval Training ◽  
T Test ◽  
Wilcoxon Test ◽  
Obese Women ◽  
High Intensity Interval Training ◽  
Before And After ◽  
High Intensity Interval

Background: Increased inflammatory mediators in obesity are associated with metabolic syndrome. Exercise is an effective effort to reduce the incidence of obesity. The High-Intensity Interval Training (HIIT) program is an exercise which include combination of high-intensity exercise and rest periods. The decrease in body fat levels due to physical training will further affect inflammatory mediators such as IL6 and TNFα. Besides training factor, genetic also play a role on obesity. One of the genes that influence obesity is the UCP2 Ala55Val gene. Objectives: This research aims to see the effect of HIIT on the levels of inflammatory mediators in obese patients based on the study of the Ala55Val UCP2 gene. Methods: This study was a Quasi-Experimental Pre and Post Design Without Control Group. Thirty obese women (BMI≥25 kg/m2) were given High-Intensity Interval Training (HIIT) as an intervention by comparing the data before and after the intervention. The training intervention was conducted for 12 weeks, consisting of two weeks of adaptation and ten weeks of HIIT intervention. The body weight, BMI and inflammatory mediators (TNFα and IL 6) before and after the intervention were analyzed using the Dependent T-Test and Wilcoxon Test as a nonparametric test. Independent T-Test and Mann Whitney test used to determine the effect of the UCP2 Ala55Val gene on changes in body weight, BMI and the inflammatory mediator. The test results were considered significantly different if p<0.05. Results: Bivariate analysis using Dependent T-Test showed that HIIT significantly improved Body Weight, BMI and IL6 with p=0.0001. Wilcoxon Test showed that HIIT significantly improved TNFα with p=0.0001. Independent T-Test showed no difference in body weight (p=0.719), BMI (p=0.663) and TNFα (p=0.264) improvement in the two genotypes of the UCP2 Ala55Val gene. Mann Whitney Test showed no difference in IL6 (p=0.288) improvement in the two genotypes of the UCP2 Ala55Val gene. Conclusion: The research concluded that the 12-week HIIT interventions improved inflammatory mediators by reducing IL6 and TNFα in obese women. There was no effect of genetic variation on the response to training intervention.

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

1995 ◽  
Vol 109 (8) ◽  
pp. 744-747 ◽  
Author(s):  
John S. Rubin ◽  
Scott Wadler ◽  
Jonathan J. Baitler ◽  
Hilda Haynes ◽  
Alla Rozenblet ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Hearing Threshold ◽  
High Dose ◽  
High Frequencies ◽  
Advanced Cervical Carcinoma ◽  
Before And After ◽  
Audiologic Testing

AbstractWR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

scholarly journals Release of Inflammatory Mediators in Association with Collection of Wound Drainage Blood during Orthopaedic Surgery

1995 ◽  
Vol 23 (6) ◽  
pp. 683-686 ◽  
Author(s):  
J. P. Arnold ◽  
M. Haeger ◽  
J. P. Bengtson ◽  
A. Bengtsson ◽  
B. Lisander
Keyword(s):  
Inflammatory Mediators ◽  
Hip Replacement ◽  
Systemic Blood ◽  
Wound Drainage ◽  
Blood Samples ◽  
Replacement Surgery ◽  
Hip Replacement Surgery ◽  
Pmn Elastase ◽  
Before And After ◽  
Pmn Élastase

Ten patients undergoing hip replacement surgery were studied regarding activation of complement and leukocytes in association with collection of wound drainage blood. The blood was collected postoperatively but not reinfused due to the possible risks with reinfusion of blood containing inflammatory mediators. Blood samples for analysis of complement activation (TCC), leukocyte activation (PMN elastase) and cytokines (Interleukin-6) were drawn preoperatively from the patients. Blood samples were also drawn intraoperatively from the wound. Samples were also drawn from the collected wound drainage blood, before and after blood was passed through a microporous filter. There were elevated concentrations of TCC, PMN elastase and IL-6 in the collected wound drainage blood before and after the filter. The filtration did not significantly reduce the concentrations of these factors. In the wound blood the concentrations were higher compared to those found in the systemic blood preoperatively, but lower compared to concentrations found in the collected drainage blood. The study demonstrates that the collection of wound drainage whole blood is associated with activation of complement, release of PMN elastase and cytokines.

scholarly journals Involvement of NO in Antinociception of NSAIDS in Murine Formalin Hind Paw Assay

Drug Research ◽  
2020 ◽  
Vol 70 (04) ◽  
pp. 145-150 ◽  
Author(s):  
Viviana Noriega ◽  
Hugo F. Miranda ◽  
Juan Carlos Prieto ◽  
Ramón Sotomayor-Zárate ◽  
Fernando Sierralta
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Dose Response ◽  
Rank Order ◽  
Linear Regression Analysis ◽  
Second Phase ◽  
Response Curves ◽  
Before And After ◽  
Two Phases ◽  
Phase Phase

AbstractThere are different animal models to evaluate pain among them the formalin hind paw assay which is widely used since some of its events appear to be similar to the clinical pain of humans. The assay in which a dilute solution of formalin is injected into the dorsal hindpaw of a murine produces two ‘phases’ of pain behavior separated by a inactive period. The early phase (Phase I) is probably due to direct activation of nociceptors and the second phase (Phase II) is due to ongoing inflammatory input and central sensitization. Mice were used to determine the potency antinociceptive of piroxicam (1,3,10,and 30 mg/kg), parecoxib (0.3, 1,3,10 and 30 mg/kg), dexketoprofen (3,10,30 and 100 mg/kg) and ketoprofen (3,10,30 and 100 mg/kg). Dose-response for each NSAIDs were created before and after 5 mg/kg of L-NAME i.p. or 5 mg/kg i.p. of 7-nitroindazole. A least-squares linear regression analysis of the log dose–response curves allowed the calculation of the dose that produced 50% of antinociception (ED50) for each drug. The ED50 demonstrated the following rank order of potency, in the phase I: piroxicam > dexketoprofen > ketoprofen > parecoxib and in the phase II: piroxicam > ketoprofen > parecoxib > dexketoprofen. Pretreatment of the mice with L-NAME or 7-nitroindazol induced a significant increase of the analgesic power of the NSAIDs, with a significant reduction of the ED50. It is suggested that NO may be involved in both phases of the trial, which means that nitric oxide regulates the bioactivity of NSAIDs.

scholarly journals Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis

2019 ◽  
Vol 8 (5) ◽  
pp. 630 ◽  
Author(s):  
Kaja Eriksson ◽  
Guozhong Fei ◽  
Anna Lundmark ◽  
Daniel Benchimol ◽  
Linkiat Lee ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Inflammatory Mediators ◽  
Gingival Crevicular Fluid ◽  
Severe Form ◽  
Oral Microbiota ◽  
Microbial Composition ◽  
Periodontal Health ◽  
Microbial Profile ◽  
Severe Periodontitis ◽  
Crevicular Fluid

This study aimed to investigate the periodontal health of patients with established rheumatoid arthritis (RA) in relation to oral microbiota, systemic and oral inflammatory mediators, and RA disease activity. Forty patients underwent full-mouth dental/periodontal and rheumatological examination, including collection of blood, saliva, gingival crevicular fluid (GCF) and subgingival plaque. Composition of plaque and saliva microbiota were analysed using 16S rRNA sequencing and levels of inflammatory mediators by multiplex-immunoassay. The majority of the patients (75%) had moderate or severe periodontitis and the rest had no/mild periodontitis. Anti-citrullinated protein antibody (ACPA) positivity was significantly more frequent in the moderate/severe periodontitis (86%) compared to the no/mild group (50%). No significance between groups was observed for RA disease duration or activity, or type of medication. Levels of sCD30/TNFRSF8, IFN-α2, IL-19, IL-26, MMP-1, gp130/sIL-6Rß, and sTNF-R1 were significantly higher in serum or GCF, and April/TNFSF13 was significantly higher in serum and saliva samples in moderate/severe periodontitis. The microbial composition in plaque also differed significantly between the two groups. In conclusion, the majority of RA patients had moderate/severe periodontitis and that this severe form of the disease was significantly associated with ACPA positivity, an altered subgingival microbial profile, and increased levels of systemic and oral inflammatory mediators.

Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4047-4047
Author(s):  
Theodore S. Hong ◽  
Vikram Deshpande ◽  
Marek Ancukiewicz ◽  
Beow Y. Yeap ◽  
Darrell R. Borger ◽  
...  
Keyword(s):  
Phase I ◽  
Cox Regression ◽  
Wald Test ◽  
Ductal Adenocarcinoma ◽  
Plasma Biomarkers ◽  
Oligometastatic Disease ◽  
Short Course ◽  
Biomarker Analysis ◽  
Before And After ◽  
A Prospective Study

4047 Background: The prognosis of resectable PDAC reflects a complex interaction between genotype, growth factor levels, and tumor microenvironment. We performed genetic, plasma, and tissue-based biomarker analysis for a phase I/II study of neoadjuvant short course proton-based chemoradiation. Methods: Patients with radiographically resectable PDAC were treated on an IRB approved, phase I/II trial of neoadjuvant short course-proton-based chemoradiation. Genotyping included KRAS, BRAF, NRAS, TP53, and PIK3CA. Tissue-based IHC on resection specimens included DPC4, CXCR4, CXCR7, and SDF1a in the central and peripheral regions of PDAC. The trial was amended to evaluate plasma biomarkers, drawn before and after chemoradiation, including HGF, VEGF, sVEGFR2, SDF1α, bFGF, PlGF, TNF-α, CAIX, sFLT1, IL-6, IL-8, and IL-1β. Correlation with OS was evaluated by the Wald test in a univariable Cox regression using log-transformed covariates. Results: Surgical specimens from all 38 patients who underwent resection and serial plasma samples from the last 12 patients enrolled were analyzed. Disease-specific results were previously reported (ASCO 2012, abs 4021). DPC4 intact (37% of evaluated patients) was associated with oligometastatic disease (p<0.05) but not OS. KRAS mutation 31/38 patients (82%), did not affect OS (HR=1.57, p=0.88) , but the specific KRAS G12D mutation (14/38, 37%) had a worse OS (HR=2.44, p<0.05). SDF1α and CXCR7 expression was higher and CXCR4 expression was lower in the tumor center versus periphery. Higher CXCR7 expression in the periphery was associated with poor OS (HR=2.29, p<0.05). High baseline plasma HGF was associated with a worse OS (HR=6.60, p<0.05), with a trend for association between high post-treatment plasma HGF and poor OS (HR=9.28, p=0.08). No other biomarker evaluated was significantly associated with OS. Conclusions: In this exploratory analysis, KRAS G12D status, CXCR7 expression, and plasma HGF level were associated with worse OS. DPC4 status correlated with oligometastatic disease. Additional IHC evaluations, including c-MET expression, are ongoing and will be reported. Clinical trial information: NCT00438256.

Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC).

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 205-205
Author(s):  
Jaspreet S. Batra ◽  
Beerinder S. Karir ◽  
Kavya Pinto-Chengot ◽  
Yuliya Jhanwar ◽  
Shankar Vallabhajosula ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Dose Escalation ◽  
Maximum Tolerated Dose ◽  
Dose Fractionation ◽  
Castration Resistant Prostate Cancer ◽  
Planar Imaging ◽  
Dose Escalation Study ◽  
Initial Portion ◽  
Before And After

205 Background: Phase I and II single dose 177Lu−J591 studies have been published. Based on the theoretical advantages of dose fractionation on safety and efficacy, we initiated a phase I dose−escalation study of fractionated−dose 177Lu−J591. Methods: Men with progressive mCRPC with normal neutrophil and platelet counts were enrolled. The initial portion was 3+3 dose−escalation, with 6 cohorts of 3−6 patients receiving 2 doses 177Lu−J591, 2 weeks apart starting with 20 mCi/m2, escalating to 45 mCi/m2. After determining maximum tolerated dose (MTD), patients enrolled in 2 expansion cohorts at recommended phase II doses (RP2D). Planar imaging of 177Lu−J591 at 6−8 days following the initial dose was performed. Pre− and post−treatment PSA was measured for all patients and the highest dose−level cohorts had CTC counts (CellSearch) measured before and after treatment. Results: 48 patients enrolled with median age 74 (55−95) ), median baseline PSA 45.38 (1.93−766.5), 37.5% with prior chemo. The RP2D’s of fractionated 177Lu−J591 were 40 mCi/m2 or 45 mCi/m2 x2 with option for GCSF. Overall PSA decline ≥ 50% in 9 (18.8%), ≥ 30% in 14 (29.2%) and any PSA decline in 26 (54.2%); at RP2D doses (n = 32), 8 (25%) with ≥ 50%, 12 (37.5%) with ≥ 30%, and 20 (62.5%) with any PSA decline. Of 25 with available CTC counts, 14 declined, 8 remained stably favorable, and 3 increased. Of 12 with unfavorable baseline CTC counts, 8 (66.7%) became favorable at follow up, 2 decreased by 30% and 88% but remained ≥ 5, and 2 increased; 1 converted from < 5 to ≥ 5. Thirty-five (72.9%) had grade 3/4 hematological toxicities; 19 (59.4%) with Gr 4 heme toxicity in RP2D cohorts, with 15 (16.9%) receiving at least 1 platelet transfusion, 6 receiving GCSF, and 0 with febrile neutropenia. Overall 4 had Gr 1 transaminitis and 14 (29.2%) had grade 1 infusion reactions (without pre−medication). Accurate targeting of 177Lu−J591 at known sites of disease seen in 84.4%. Conclusions: Fractionated 177Lu−J591 is well tolerated with predictable, reversible myelosuppression, achieving a higher cumulative dose than possible with a single dose. Both PSA and CTC count control was achieved. Clinical trial information: NCT00538668.

Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 261-261 ◽  
Author(s):  
Douglas Campbell ◽  
Dhanusha Sabanathan ◽  
Howard Gurney ◽  
David Gillatt ◽  
Marko Trifunovic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase 1 ◽  
Standard Of Care ◽  
The Body ◽  
Whole Body ◽  
Chimeric Antibody ◽  
Pharmacokinetic Data ◽  
Post Dose ◽  
Before And After

261 Background: Miltuximab is a chimeric antibody targeting Glypican-1 which is overexpressed in prostate cancer. Miltuximab has shown promising safety and efficacy in radioimmunotherapy models of prostate cancer. Methods: Metastatic patients (prostate, pancreatic and bladder) were dosed with unlabelled Miltuximabfollowed by the infusion of 1 mg/250MBq 67Ga-Miltuximab. Patients underwent whole body gamma and SPECT/CT scans up to 144 hours post-infusion. Standard of care imaging was performed at least 14 days before and after participation. Safety was evaluated by an external monitoring committee. Total organ exposure was determined by dosimetry of whole-body gamma scans. Antibody pharmacokinetics were also determined. Results: 12 patients were enrolled into the trial. Miltuximabwas well tolerated and did not elicit any drug-related adverse reactions. Liver and spleen uptake of 67Ga-Miltuximabwas observed from 30 min to 72 hours post dose. Pre-infusion of unlabelled Miltuximab resulted in reduced liver accumulation and increased distribution in the rest of the body. Miltuximab targeting to sites of active progressive disease was observed in certain prostate cancer patients who had failed enzalutamide treatment. Dosimetry analysis combined with antibody pharmacokinetic data was used to establish safe dose limits for a Phase 1 study. Conclusions: This study is the first in human for Miltuximaband demonstrates its potential for further clinical evaluation as a theranostic in prostate cancers and formed the basis for a Phase I imaging and therapy study planned for 2019. This study will use 89Zr-labelled Miltuximab to screen eligible patients and confirm tumour localisation, followed by treatment with 177Lu-labelled Miltuximab. Clinical trial information: ACTRN12616000787482.

Sign in / Sign up

Export Citation Format

Share Document